Cost comparison of tinzaparin versus enoxaparin as deep venous thrombosis prophylaxis in spinal cord injury: preliminary data.
Thromboembolic events are major causes of morbidity and mortality in patients with spinal cord injuries. Low molecular weight heparins are recommended as prophylaxis against such events. The purpose of the current study was to perform a cost analysis of tinzaparin versus enoxaparin using published efficacy and safety data as deep vein thrombosis and pulmonary embolism prophylaxis in this population. All published English language articles evaluating either tinzaparin or enoxaparin as pharmacoprophylaxis in spinal cord-injured patients were identified. Data from these studies were subjected to cost-effectiveness analyses followed by sensitivity analyses to determine which agent is the most cost-effective in these patients. Results demonstrated that tinzaparin 3500 U daily and enoxaparin 30 mg every 12 h are both cost-effective agents for thromboembolism prophylaxis in patients with spinal cord injuries.
Wade
W E
WE
The authors are with the College of Pharmacy, University of Georgia, Athens 30602, USA. bwade@mail.rx.uga.edu
Spruill
W J
WJ
D003362:Cost-Benefit Analysis; D003625:Data Collection; D004334:Drug Administration Schedule; D017984:Enoxaparin / Q000008:administration & dosage / Q000191:economics* / Q000592:standards; D005343:Fibrinolytic Agents / Q000191:economics* / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000191:economics* / Q000592:standards; D006801:Humans; D011655:Pulmonary Embolism / Q000188:drug therapy / Q000191:economics / Q000517:prevention & control; D013119:Spinal Cord Injuries / Q000150:complications* / Q000188:drug therapy / Q000191:economics; D013810:Therapeutic Equivalency; D000078222:Tinzaparin; D020246:Venous Thrombosis / Q000188:drug therapy / Q000191:economics / Q000517:prevention & control*
D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D000078222:Tinzaparin